<p>Metabotropic glutamate receptor 7 (mGlu₇) is a G protein-coupled receptor (GPCR) involved in neurotransmitter release throughout the central nervous system (CNS). Low levels of the receptor are correlated with intellectual disability, autism, repetitive behaviors, and seizures in patients with neurodevelopmental disorders (NDDs), including the disease Rett syndrome. These findings suggest that increasing mGlu₇ activity may be of therapeutic benefit. In the current manuscript, we report the characterization of a novel transgenic mouse that overexpresses the human <i>GRM7B</i> splice variant at approximately fivefold higher levels compared to wild-type (WT) littermates. These animals exhibit a reciprocal decrease in expression of the mouse mGlu_7A splice isoform, suggesting feedback regulation of receptor expression. Previous studies from our lab and others have shown that mGlu₇ activation is permissive for long-term potentiation induction in the hippocampus and amygdala. Here, we identified subtle differences in agonist-modulated hippocampal field recordings in mice overexpressing mGlu_7B, but no changes in theta burst-induced long-term potentiation. Our lab previously characterized behavioral phenotypes in <i>Grm7</i>^{<i>−/−</i>} animals that were observed in other animal models of NDDs. Surprisingly, we find here that mGlu_7B-overexpressing mice exhibit similar phenotypes to previously reported studies in <i>Grm7</i>^{<i>−/−</i>} animals in repetitive behavior and cognition assays. Overall, these findings suggest that precise control of mGlu₇ may be required to avoid abnormal phenotypes.</p>